Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

Conroy, Thierry; Lamfichekh, Najib; Etienne, Pierre-Luc; Rio, Emmanuel; François, Éric; Mesgouez‐Nebout, Nathalie; Vendrely, V.; Artignan, Xavier; Bouché, Olivier; Gargot, D.; Boige, Valérie; Bonichon-Lamichhane, Nathalie; Louvet, Christophe; Morand, Clotilde; de la Fouchardière, Christelle; Juzyna, Béata; Rullier, Éric; Marchal, Frédéric; Castan, Florence; Borg, Christophe

doi:10.1200/jco.2020.38.15_suppl.4007

Public

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

Published in Journal of Clinical Oncology • May 20, 2020

Authors:

Thierry Conroy

Najib Lamfichekh

Pierre-Luc Etienne

Abstract

4007 Background: PRODIGE 23 investigated the role of neoadjuvant mFOLFIRINOX before preoperative (preop) chemoradiation (CRT), with TME-surgery and adjuvant chemotherapy (CT) in resectable locally advanced rectal cancer. Methods: PRODIGE 23 is a phase III multicenter randomized clinical trial. Eligi...

Subject

Medicine

Capecitabine

Hazard ratio

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!